Clinical Trial: A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309276) titled 'A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer' on Dec. 15.

Brief Summary: This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficacy of JS212 combined with JS207, Toripalimab, JS213 combined or not combined with chemotherapy.

Study Start Date: Dec. 30

Study Type: INTERVENTIONAL

Condition: Advanced Lung Cancer

Intervention: DRUG: JS212 for Injectio...